Palisade bio announces notice of allowance for canadian patent covering lead product candidate, pali-2108

Pali-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure company on track to commence phase 1 human clinical study of pali-2108 for the treatment of uc before year end carlsbad, ca, june 11, 2024 (globe newswire) -- palisade bio, inc.  (nasdaq: pali) (“palisade” or the “company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the canadian intellectual property office (cipo) has issued a notice of allowance for patent application number 3,174,137 titled, “gut microbiota bioactivated pde4 inhibitor precursors.” this patent covers the composition of pali-2108, the company's orally administered, locally acting colon-specific phosphodiesterase-4 (pde4) inhibitor prodrug in development for patients affected by ulcerative colitis (uc).
PALI Ratings Summary
PALI Quant Ranking